Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders.
The first close of the Series A round was led by Baltimore-based Camden Partners Nexus and Savoir Capital.
The company’s initial drug candidate, LPT99, moved into the clinical phase of a Phase I study this month. In the fall, the company reported positive feedback from the U.S. Food and Drug Administration in response to an initial submission, which plans to develop the treatment for the prevention of chemotherapy-induced hearing loss in pediatric patients. The company is also exploring further use for other types of hearing loss.
“This round of financing allows us to take LPT99 into the clinic and further validates our development strategy,” said Hugo Peris, founder and CEO of Spiral Therapeutics.
Launched in early 2016, the San Francisco–based company has a research and development presence in Baltimore through a collaboration with Johns Hopkins, as well as in Barcelona, Spain.
“Spiral Therapeutics brings together innovative therapies addressing inner ear disorders and a seasoned and energetic management team,” George Petrocheilos, a general partner at Camden Partners who will join the company’s board, said in a statement. “Its solid R&D foundation and the meaningful collaborations with leading medical institutions like Johns Hopkins and UCSF make Spiral an ideal investment for Camden.”
Camden Partners Nexus, the biomedical-focused venture fund of Inner Harbor–based Camden Partners that focuses on companies commercializing research, recently made investments in local startups including Sisu Global Health and WindMIL Therapeutics, among other deals since making its final close at the end of 2017.
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!